Steris Raises EPS Outlook Amid Strong Growth; AST Adjusts Guidance
What happened
Steris reported $1.6 billion in revenue for the quarter ended September 30, with adjusted EPS reaching $2.94. The company raised its fiscal 2027 adjusted EPS outlook to a range of $11.35 to $11.55. Meanwhile, competitor AST reported $295.6 million in revenue, and adjusted its organic growth outlook to 6-7%.
From themarketsdaily.com
Why it matters
The results show differing performance between the two medical device competitors. Steris saw Healthcare revenue grow 9% and Life Sciences revenue grow 18%, leading to an increased full-year expectation. AST saw its capital equipment revenue fall 21% during the quarter.
From themarketsdaily.com
Who's involved
- ASTCompetitor in the medical device market
- SterisMedical device company that raised its full-year EPS outlook
- Boston PartnersInvestment management corporation that purchased a new stake in Steris
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Boston PartnersSpeculative
Boston Partners might see improved investment value due to Steris's raised EPS outlook and restructuring plan.